Jane Pritchett Henderson
Jane Pritchett Henderson has more than 29 years of experience in the life sciences industry and health care investment banking. She currently serves as Chief Financial Officer at Turnstone Biologics, a clinical-stage immuno-oncology company. Prior to Turnstone, Ms. Henderson served as Senior Vice President of Corporate Development at Voyager Therapeutics, a publicly-traded, clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Prior to Voyager, Ms. Henderson served as Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., having joined the privately held biopharmaceutical company in 2013 and leading the sale of Kolltan to Celldex Pharmaceuticals, Inc. in late 2016. Previously, Ms. Henderson served as Vice President, Business Development of ISTA Pharmaceuticals, Inc., until ISTA Pharmaceuticals was acquired by Bausch + Lomb. Prior to ISTA Pharmaceuticals, Ms. Henderson served as Chief Financial Officer and Head of Business Development at Axerion Pharmaceuticals, Inc., and as Chief Financial Officer and Chief Business Officer of Panacos Pharmaceuticals, Inc. In addition to her industry experience, Ms. Henderson’s extensive healthcare investment banking experience includes the execution of more than 95 mergers and acquisitions, advisory and financing deals as managing director and other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson holds a B.S. in psychology from Duke University and currently serves on the board of directors of Sesen Bio Inc., a publicly-traded biologics oncology company.